Rx PA Drug Treatment Criteria

Prescription Drug Prior Authorization (Rx PA) Drug Treatment Criteria

For Medicare Dual Choice Cal MediConnect Plan (Medicare-Medicaid Plan) Formulary and Criteria information, please visit the page here: Medicare Dual Choice Cal MediConnect Plan


To provide access to quality and clinically effective medications, IEHP uses a drug formulary. The IEHP Formulary provides information regarding medications covered under the benefit plans.

Please note that coverage is not limited only to drugs on the IEHP Formulary.  Many drugs not listed on the Formulary are covered through the Rx Prior Authorization Process.

  • Rx prior authorization encourages the appropriate and rational use of medications by allowing coverage only when certain conditions are met.
  • The Rx prior authorization program is based upon current medical findings, FDA-approved manufacturer labeling information, and recommendation by the IEHP Pharmacy and Therapeutics Subcommittee.
  • If the medication you prescribe  is not on IEHP Formulary, you or the pharmacist may request authorization for the medication by submitting an IEHP Prescription Drug Prior Authorization Request Form (Rx PA)  to IEHP. If the request is approved, you will be notified and the medication will be covered. If the request is denied, you and your patient will be notified of the decision.

Any medication not on the IEHP Formulary requires Rx Prior Authorization to be covered by IEHP.

The medications requiring Rx Prior Authorization are subject to change.

First line Formulary medications should be used instead of the Non-Formulary medications.  Drugs with specific criteria / guidelines are listed here:  

Medi-Cal PA Drug Criteria Summary Table - Click Here (Effective Jan 1 2019)

To view Drug Criteria Referenced in Summary Table - Click Links Below:

Clinical Practice Guidelines - CPGs

Drug Prior Authorization Criteria

Drug Class Prior Authorization Criteria

  • Adult Enteral Nutritional SupplementView »

  • Antineoplastic AgentsView »

  • Botulinum ToxinView »

  • Erythropoieses-stimulating Agents (ESAs)View »

  • Growth HormonesView »

  • Hepatitis C (Effective Jan 1 2019)View »

  • Hereditary AngioedemaView »

  • Immuno GlobulinsView »

  • Intravenous Antibiotics (Effective Jan 1 2019)View »

  • Nutritional Supplement Infant FormulaView »

  • Opioid AnalgesicsView »

  • Pediatric Enteral Nutritional SupplementView »

  • Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) InhibitorView »

  • Testosterone Hormone ReplacementView »

  • Therapeutic Agents in Rheumatic And Inflammatory DiseasesView »

  • Transplant ImmunosuppressantsView »

  • Viscosupplementation ProductsView »

Pharmacy Policies

  • Adult VaccineView »

  • Antibiotic Stewardship (Effective Jan 1 2019)View »

  • Automatic Blood Pressure Monitor Coverage PolicyView »

  • Brand Name Drug Policy (Effective Jan 1 2019)View »

  • Continuous Glucose Monitoring DevicesView »

  • Drug Trial and FailureView »

  • External Insulin Pump PolicyView »

  • Hepatitis B&C Center of Excellence (COE) - (Effective Jan 1, 2019)View »

  • High Daily Morphine Milligram EquivalentView »

  • IEHP Prescription Drug Prior Authorization Drug Treatment Criteria and Policy (Effective Jan 1 2019)View »

  • Intrauterine and Subdermal Contraceptive DevicesView »

  • Nebulizer PolicyView »

  • Non-Formulary Drug Policy (Non-Medicare)View »

  • Non-Sterile Compounded MedicationView »

  • Off-Label Indications of Non-Formulary DrugsView »

  • Pain ManagementView »

  • Quantity LimitsView »

  • Transgender Hormonal Treatment for AdultsView »

  • Transgender Hormonal Treatment for PediatricsView »